Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

322 LEFLUNOMIDE
(2003): Canonne-Courivaud D+, Ann Dermatol Venereol
130(4), 435
Purpura (1–10%)
Rash (sic) (10%)
(2006): Chan V+, Pharmacoepidemiol Drug Saf 15(7), 485
(2006): Shastri V+, Indian J Dermatol Venerol Leprol 72(4), 286
(2002): Hirohata S, Nippon Rinsho 60(12), 2357
(2002): Sanders S+, Am J Med Sci 323(4), 190
(2001): Cohen S+, Arthritis Rheum 44(9), 1984
(2000): Emery P+, Rheumatology (Oxford) 39, 655
(2000): Nousari HC+, Arch Dermatol 136, 1204
(1999): Goldenberg MM, Clin Ther 21, 1837
(1999): Smolen JS+, Lancet 353, 259
(1997): Silva Junior HT+, Am J Med Sci 313, 289
(1995): Mladenovic V+, Arthritis Rheum 38, 1595
Squamous cell carcinoma
(2002): Shelley J (from Internet) (observation)
Stevens–Johnson syndrome
Toxic epidermal necrolysis
(2006): Teraki Y+, Int J Dermatol 45(11), 1370
(2003): Fischer TW+, Dermatology 207(4), 386
Ulcerations (1–10%)
(2006): Jakob A+, J Dtsch Dermatol 4(4), 324
Urticaria (